Skip to content

Author

G. Esendagli

We have 4 of 135 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Immune Checkpoint Dysfunction Remodels Adaptive Immune Receptor Repertoires in CTLA-4 Insufficiency and LRBA Deficiency

It is demonstrated that inherited disruption of the CTLA-4/LRBA axis profoundly remodels AIRRs, preferentially affecting CD8⁺ T-cell diversity while also constraining humoral immunity, and highlight a central role for this immune checkpoint pathway in maintaining adaptive immune repertoire diversity and clonal homeosta...

Gökhan Cildir, Selin Cildir, Rahmi Kutay Erdogan et al. · 0 citations
Open access Oct 2026

IFN-γ, TNF-α, IL-10, IL-17 and IL-22 secretion capacities and activation profile of T cells in psoriatic arthritis patients under disease-modifying antirheumatic drug therapy

Introduction While biologic disease-modifying antirheumatic drugs (bDMARDs) have transformed management, achieving complete remission remains a challenge due to complex immune networks in Psoriatic arthritis (PsA). This study aimed to characterize the functional modulation of circulating T-helper (Th) and cytotoxic T (...

Sibel Goksen, G. Ayan, U. Kalyoncu et al. · 0 citations
Open access Aug 2026

Codelivery of nivolumab and Galunisertib by EGFR-targeted spherical polymeric nanoparticles for effective treatment of non-small cell lung cancer.

A novel nanosystem was developed by co-loading galunisertib, a TGF-β inhibitor, and nivolumab into spherical nanoparticles composed of PLGA derivatives conjugated with anti-EGFR for targeted delivery that maintained antitumor activity comparable to the free-drug combination while enabling tumor-directed delivery and sh...

Meryem Kaplan, E. Tavukçuoğlu, S. Öztürk et al. · 0 citations
Open access Sep 2026

Dual-antigen AdV5 vaccines against Crimean-Congo hemorrhagic fever virus induce superior humoral and Th1-biased cellular immunity

Immunization with adenovirus serotype 5 (AdV5) vectors expressing CCHFV antigens elicited potent humoral and cellular immune responses, conferring 100% protection against lethal viral challenge across the majority of evaluated formulations.

A. Hanifehnezhad, S. Oztop, E. Tavukçuoğlu et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.